Prescient Therapeutics’ PTX-100 for peripheral T-cell lymphoma treatment granted US orphan drug status
Prescient Therapeutics Ltd (ASX:PTX)’s PTX-100 for the treatment of peripheral T-cell lymphomas (PTCL) has been...
Prescient Therapeutics Ltd (ASX:PTX)’s PTX-100 for the treatment of peripheral T-cell lymphomas (PTCL) has been...
Prescient Therapeutics Ltd (ASX:PTX) has been granted a US patent for its flagship OmniCAR portfolio entitled...
All the major banks have now lifted interest rates in line with the Reserve Bank...
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke outlines the company's oncology treatment vision in a new...
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke explains how the company is combatting the leading, global...
Prescient Therapeutics Ltd (ASX:PTX) has signed an agreement related to advancing a new research program with...
Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive...
The company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.